

In-vitro Colorectal Cancer Screening Tests Market Size, Share & Trends Analysis Report By Test (Fecal Occult Blood Tests, Biomarker Tests), By End-use (Hospitals & Clinics, Diagnostic Laboratories), By Region, And Segment Forecasts, 2025 - 2030

<https://marketpublishers.com/r/I37309AC9D86EN.html>

Date: March 2025

Pages: 129

Price: US\$ 5,950.00 (Single User License)

ID: I37309AC9D86EN

Abstracts

This report can be delivered to the clients within 3 Business Days

In-vitro Colorectal Cancer Screening Tests Market Growth & Trends

The global in-vitro colorectal cancer screening tests market size is expected to reach USD 1.7 billion by 2030, registering a CAGR of 4.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising number of novel screening models to combat the increasing incidences of colon and rectal malignancy cases is the major factor influencing the market growth. The emergence of newly developed genetic and biomarker tests such as tumor M2-PK stool tests and methylated gene testing is anticipated to drive the adoption rate of tumor diagnostic models.

The increasing incidence of colorectal malignancy is a significant driver for the growth of the segment. For example, according to data released by the National Cancer Center Japan in June 2022, it was projected that there would be approximately 1,019,000 new cases of cancer in Japan in 2022, with Colorectal Cancer (CRC) accounting for an estimated 158,200 new cases. Similarly, data updated by Cancer Australia in August 2022 indicated that 15,713 new cases of CRC were expected to be diagnosed in Australia in 2022, with 8,300 cases among males and 7,413 cases among females. As a result, the increasing prevalence of colorectal malignancy is anticipated to drive the demand for colonoscopy devices.

The implementation of various initiatives by public organizations to promote screening has positively impacted the demand for in-vitro CRC screenings. For instance, according to reports from Cancer.org, healthcare systems in California continued to provide FIT kits (fecal immunochemical tests) during the months of April and May 2020, and the response rates for FIT remained high despite the onset of the COVID-19 pandemic. Additionally, the European Cancer community has mobilized its resources to evaluate, address, and mitigate the adverse effects of COVID-19 on screening. These efforts have contributed to the sustained demand for in-vitro screening tests.

Furthermore, market growth is expected to be driven by the increasing number of product launches by major market players. These product launches are aimed at providing access to technologically advanced and innovative products. For instance, Pillar Biosciences, Inc. received FDA approval for the ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) in July 2021 for the detection of CRC.

In-vitro Colorectal Cancer Screening Tests Market Report Highlights

The fecal occult blood tests segment dominated the in-vitro colorectal cancer screening tests industry, with the largest revenue share of 82.3% in 2024. The biomarker tests segment is anticipated to emerge as the fastest-growing segment and grow at a CAGR of 5.8% from 2025 to 2030.

The diagnostic laboratories segment held the largest revenue share in 2024, attributed to their advanced technology, high accuracy, and comprehensive testing capabilities. The hospitals and clinics segment is expected to grow at a significant pace during the forecast period, fueled by the increasing demand for early diagnosis and noninvasive testing options.

North America in-vitro colorectal cancer screening tests market dominated the global market with the largest revenue share of 39.5% in 2024. The U.S. in-vitro colorectal cancer screening tests market held the largest share in 2024.

Asia Pacific in-vitro colorectal cancer screening tests market is set to expand at the fastest CAGR of 5.2% from 2025 to 2030.

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
 - 1.2.1. Test
 - 1.2.2. End Use
 - 1.2.3. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
 - 1.5.1. Purchased Database
 - 1.5.2. GVR's Internal Database
 - 1.5.3. Secondary Sources
 - 1.5.4. Primary Research
- 1.6. Information Analysis
 - 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
 - 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot

CHAPTER 3. IN-VITRO COLORECTAL CANCER SCREENING TESTS MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
 - 3.2.1. Market Driver Analysis
 - 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
 - 3.3.1. Industry Analysis - Porter's Five Forces Analysis

- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrant
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis

CHAPTER 4. IN-VITRO COLORECTAL CANCER SCREENING TESTS MARKET: TEST BUSINESS ANALYSIS

- 4.1. Test Market Share, 2024 & 2030
- 4.2. Test Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, By Test, 2018 to 2030 (USD Million)
- 4.4. Fecal Occult Blood Tests
 - 4.4.1. Fecal Occult Blood Tests Market, 2018 - 2030 (USD Million)
 - 4.4.2. Guaiac FOB Stool Test
 - 4.4.2.1. Guaiac FOB Stool Test Market, 2018 - 2030 (USD Million)
 - 4.4.3. Immuno-FOB Agglutination Test
 - 4.4.3.1. Immuno-FOB Agglutination Test Market, 2018 - 2030 (USD Million)
 - 4.4.4. Lateral Flow Immuno-FOB Test
 - 4.4.4.1. Lateral Flow Immuno-FOB Test Market, 2018 - 2030 (USD Million)
 - 4.4.5. Immuno-FOB ELISA Test
 - 4.4.5.1. Immuno-FOB ELISA Test Market, 2018 - 2030 (USD Million)
- 4.5. Biomarker Tests
 - 4.5.1. Biomarker Tests Market, 2018 - 2030 (USD Million)
- 4.6. Other Methods
 - 4.6.1. Other Methods Market, 2018 - 2030 (USD Million)

CHAPTER 5. IN-VITRO COLORECTAL CANCER SCREENING TESTS MARKET: END USE BUSINESS ANALYSIS

- 5.1. End Use Market Share, 2024 & 2030
- 5.2. End Use Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, By End Use, 2018 to 2030 (USD Million)
- 5.4. Hospitals and Clinics
 - 5.4.1. Hospitals and Clinics Market, 2018 - 2030 (USD Million)
- 5.5. Diagnostic Laboratories
 - 5.5.1. Diagnostic Laboratories Market, 2018 - 2030 (USD Million)

5.6. Others

5.6.1. Others Market, 2018 - 2030 (USD Million)

CHAPTER 6. IN-VITRO COLORECTAL CANCER SCREENING TESTS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

6.1. Regional Market Share Analysis, 2024 & 2030

6.2. Regional Market Dashboard

6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:

6.4. North America

6.4.1. North America In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.4.2. U.S.

6.4.2.1. Key Country Dynamic

6.4.2.2. Regulatory Framework

6.4.2.3. Competitive Insights

6.4.2.4. U.S. In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.4.3. Canada

6.4.3.1. Key Country Dynamic

6.4.3.2. Regulatory Framework

6.4.3.3. Competitive Insights

6.4.3.4. Canada In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.4.4. Mexico

6.4.4.1. Key Country Dynamic

6.4.4.2. Regulatory Framework

6.4.4.3. Competitive Insights

6.4.4.4. Mexico In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.5. Europe

6.5.1. Europe In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.5.2. U.K.

6.5.2.1. Key Country Dynamic

6.5.2.2. Regulatory Framework

6.5.2.3. Competitive Insights

6.5.2.4. U.K. In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.5.3. Germany

6.5.3.1. Key Country Dynamic

6.5.3.2. Regulatory Framework

6.5.3.3. Competitive Insights

6.5.3.4. Germany In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.5.4. Spain

6.5.4.1. Key Country Dynamic

6.5.4.2. Regulatory Framework

6.5.4.3. Competitive Insights

6.5.4.4. Spain In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.5.5. France

6.5.5.1. Key Country Dynamic

6.5.5.2. Regulatory Framework

6.5.5.3. Competitive Insights

6.5.5.4. France In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.5.6. Italy

6.5.6.1. Key Country Dynamic

6.5.6.2. Regulatory Framework

6.5.6.3. Competitive Insights

6.5.6.4. Italy In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.5.7. Denmark

6.5.7.1. Key Country Dynamic

6.5.7.2. Regulatory Framework

6.5.7.3. Competitive Insights

6.5.7.4. Denmark In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.5.8. Sweden

6.5.8.1. Key Country Dynamic

6.5.8.2. Regulatory Framework

6.5.8.3. Competitive Insights

6.5.8.4. Sweden In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.5.9. Norway

6.5.9.1. Key Country Dynamic

6.5.9.2. Regulatory Framework

6.5.9.3. Competitive Insights

6.5.9.4. Norway In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.6. Asia Pacific

6.6.1. Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.6.2. Japan

6.6.2.1. Key Country Dynamic

6.6.2.2. Regulatory Framework

6.6.2.3. Competitive Insights

6.6.2.4. Japan In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.6.3. China

6.6.3.1. Key Country Dynamic

6.6.3.2. Regulatory Framework

6.6.3.3. Competitive Insights

6.6.3.4. China In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.6.4. India

6.6.4.1. Key Country Dynamic

6.6.4.2. Regulatory Framework

6.6.4.3. Competitive Insights

6.6.4.4. India In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.6.5. South Korea

6.6.5.1. Key Country Dynamic

6.6.5.2. Regulatory Framework

6.6.5.3. Competitive Insights

6.6.5.4. South Korea In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.6.6. Australia

6.6.6.1. Key Country Dynamic

6.6.6.2. Regulatory Framework

6.6.6.3. Competitive Insights

6.6.6.4. Australia In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.6.7. Thailand

6.6.7.1. Key Country Dynamic

6.6.7.2. Regulatory Framework

6.6.7.3. Competitive Insights

6.6.7.4. Thailand In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.7. Latin America

6.7.1. Latin America In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.7.2. Brazil

6.7.2.1. Key Country Dynamic

6.7.2.2. Regulatory Framework

6.7.2.3. Competitive Insights

6.7.2.4. Brazil In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.7.3. Argentina

6.7.3.1. Key Country Dynamic

6.7.3.2. Regulatory Framework

6.7.3.3. Competitive Insights

6.7.3.4. Argentina In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.8. Middle East and Africa

6.8.1. Middle East and Africa In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.8.2. South Africa

6.8.2.1. Key Country Dynamic

6.8.2.2. Regulatory Framework

6.8.2.3. Competitive Insights

6.8.2.4. South Africa In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.8.3. Saudi Arabia

6.8.3.1. Key Country Dynamic

6.8.3.2. Regulatory Framework

6.8.3.3. Competitive Insights

6.8.3.4. Saudi Arabia In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.8.4. UAE

6.8.4.1. Key Country Dynamic

6.8.4.2. Regulatory Framework

6.8.4.3. Competitive Insights

6.8.4.4. UAE In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

6.8.5. Kuwait

6.8.5.1. Key Country Dynamic

6.8.5.2. Regulatory Framework

6.8.5.3. Competitive Insights

6.8.5.4. Kuwait In-vitro Colorectal Cancer Screening Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 7. COMPETITIVE LANDSCAPE

7.1. Participant Overview

7.2. Company Market Position Analysis

7.3. Company Categorization

7.4. Strategy Mapping

7.5. Company Profiles/Listing

7.5.1. Abbott

7.5.1.1. Participant's Overview

7.5.1.2. Financial Performance

7.5.1.3. Product Benchmarking

7.5.1.4. Strategic Initiatives

7.5.2. Epigenomics AG

7.5.2.1. Participant's Overview

7.5.2.2. Financial Performance

7.5.2.3. Product Benchmarking

7.5.2.4. Strategic Initiatives

7.5.3. Beckman Coulter, Inc.

7.5.3.1. Participant's Overview

7.5.3.2. Financial Performance

7.5.3.3. Product Benchmarking

7.5.3.4. Strategic Initiatives

7.5.4. Eiken Chemical Co., Ltd.

7.5.4.1. Participant's overview

7.5.4.2. Financial Performance

7.5.4.3. Product Benchmarking

7.5.4.4. Strategic Initiatives

7.5.5. Sysmex Corporation

7.5.5.1. Participant's Overview

7.5.5.2. Financial Performance

7.5.5.3. Product Benchmarking

7.5.5.4. Strategic Initiatives

- 7.5.6. Siemens Healthineers AG
 - 7.5.6.1. Participant's Overview
 - 7.5.6.2. Financial Performance
 - 7.5.6.3. Product Benchmarking
 - 7.5.6.4. Strategic Initiatives
- 7.5.7. Quest Diagnostics Incorporated
 - 7.5.7.1. Participant's Overview
 - 7.5.7.2. Financial Performance
 - 7.5.7.3. Product Benchmarking
 - 7.5.7.4. Strategic Initiatives
- 7.5.8. Oncocyte Corporation
 - 7.5.8.1. Participant's Overview
 - 7.5.8.2. Financial Performance
 - 7.5.8.3. Product Benchmarking
 - 7.5.8.4. Strategic Initiatives
- 7.5.9. Merck KGaA
 - 7.5.9.1. Participant's Overview
 - 7.5.9.2. Financial Performance
 - 7.5.9.3. Product Benchmarking
 - 7.5.9.4. Strategic Initiatives
- 7.5.10. Immunostics Inc.
 - 7.5.10.1. Participant's Overview
 - 7.5.10.2. Financial Performance
 - 7.5.10.3. Product Benchmarking
 - 7.5.10.4. Strategic Initiatives
- 7.5.11. Kyowa Kirin Co., Ltd.
 - 7.5.11.1. Participant's Overview
 - 7.5.11.2. Financial Performance
 - 7.5.11.3. Product Benchmarking
 - 7.5.11.4. Strategic Initiatives
- 7.5.12. Randox Laboratories Ltd.
 - 7.5.12.1. Participant's Overview
 - 7.5.12.2. Financial Performance
 - 7.5.12.3. Product Benchmarking
 - 7.5.12.4. Strategic Initiatives
- 7.5.13. R-Biopharm AG
 - 7.5.13.1. Participant's Overview
 - 7.5.13.2. Financial Performance
 - 7.5.13.3. Product Benchmarking

7.5.13.4. Strategic Initiatives

I would like to order

Product name: In-vitro Colorectal Cancer Screening Tests Market Size, Share & Trends Analysis Report By Test (Fecal Occult Blood Tests, Biomarker Tests), By End-use (Hospitals & Clinics, Diagnostic Laboratories), By Region, And Segment Forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/I37309AC9D86EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I37309AC9D86EN.html>